ArticleBiologics : targets & therapy2019

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up.

Alok Chandra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.